However, the management of anemia in low- and very low-risk MDS patients involves ESAs, granulocyte-macrophage colony-stimulating factor, lenalidomide for 5q- and other MDS, luspatercept, and hypomethylating agents [44]. The gene discussed is CSF2; the disease is anemia (phenotype).